In this episode of Second Opinion, Christina Farr and Luba Greenwood chat with Mike Desjadon, CEO of Anomaly Health, about the state of American healthcare heading into 2025.
Because so many of you asked for it!
Plus, some thoughts about Transcarent buying Accolade!
Things have gotten a little better in digital health VC land, but it’s still challenging out there!
How I’ve been thinking about recent events
Ash Zenooz and Luba Greenwood interview Andrea Ippolito about her extensive career in healthcare spanning academia, government, and the private sector, as well as her current role as founder and CEO of SimpiFed. They discuss the intricacies of government roles, the importance of women's health, and
Health care VCs are flocking to AI - and it’s all starting to feel a lot like crypto
Luba Greenwood and Ash Zenooz discuss the evolving biotech landscape, the impact of AI on drug discovery, the importance of using real-world evidence in drug development, and personal motivations for continuing efforts in the biotech field.
I teamed up with two health policy experts to explore the bull and bear case.
Christina Farr, Ash Zenooz, and Luba Greenwood are joined by Zeke Emanuel, a prominent oncologist, bioethicist, and influential voice in healthcare to discuss the impact of GLP-1 drugs, healthcare affordability, Trump's appointments, and AI in medicine. The second half of the episode was recorded a
The company closed up shop abruptly this week.
Lessons learned after a strategy shift featuring Brightline CEO Naomi Allen and investor Alyssa Jaffee
